Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 24

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 24
---
, the term “office holders” includes
directors and certain officers, including the general manager (i. e., chief executive officer, or CEO), chief business manager, deputy
CEO, vice CEO, any other person assuming the responsibilities of any of the foregoing positions without regard to such person’s
title, and any director or manager who reports directly to the CEO. The compensation policy serves as the basis for determining the financial
terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation
of payment in respect of employment or engagement. The compensation policy must relate to certain factors specified in the Companies Law,
including advancement of the company’s objectives, the company’s business and its long-term strategy, and creation of appropriate
incentives for executives. It must also consider, among other things, the company’s risk management, size and the nature of its
operations. The Companies Law describes what factors have to be considered by, and what principles must be included in, the compensation
policy.

Our current compensation policy was adopted in June 2024, at
an annual general meeting of our shareholders, following the recommendation of our compensation committee and our board of directors,
and will remain in effect for a period of three years unless restated prior, in accordance with the Companies Law. In accordance with
Nasdaq listing standards, under Rule 10D-1, we have adopted on August 16, 2023, a clawback policy.

Approvals Required for Compensation of Directors and Officers

Under the Companies Law, the compensation of each of our directors
and our CEO requires the approval of our compensation committee, the subsequent approval of the board of directors and, unless exempted
under the regulations promulgated under the Companies Law, the approval of our shareholders at a general meeting (in the case of our CEO,
the shareholder approval must include the special majority described under “ Item 6. Directors, Senior Management and Employees - C.
Board Practices - Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of an Office
Holder and Approval of Certain Transactions”). The compensation of any other office holder (who is neither a director nor our Chief
Executive Officer), if consistent with our compensation policy, requires the approval of our compensation committee, followed by our board
of directors. Compensation of any such office holder that deviates from our compensation policy also requires shareholders’ approval,
including by the special majority described under “ Item 6. Directors, Sen